Response to Moreno-Vílchez et al., "Baricitinib for the treatment of alopecia areata in adults: Real world analysis of 36 patients"

J Am Acad Dermatol. 2024 Aug;91(2):e39-e40. doi: 10.1016/j.jaad.2024.02.064. Epub 2024 Apr 16.

Authors

Deesha Desai¹, Ambika Nohria², Jerry Shapiro², Kristen Lo Sicco²

Affiliations

¹ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Electronic address: [email protected].
² The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.

PMID: 38631444
DOI: 10.1016/j.jaad.2024.02.064

No abstract available

Keywords: Janus kinase inhibitor; alopecia areata; baricitinib; medication safety.

Publication types

Letter

MeSH terms

Adult
Alopecia Areata* / drug therapy
Female
Humans
Male
Pyrazoles* / therapeutic use
Sulfonamides* / therapeutic use
Treatment Outcome

Substances

Pyrazoles
Sulfonamides